We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-7.32%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
10 Year Est. Return
AUM
$198M
AUM Growth
-$9.76M
Cap. Flow
+$7.91M
Cap. Flow %
4%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$7.91M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BIOR
1
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$129M 65.06%
108,127
AMYT
2
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$63M 31.84%
4,520,000
SCTL
3
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$6.14M 3.11%
+2,202,420
New +$7.91M

Similar funds

Athyrium Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Athyrium Capital Management held 3 positions worth $198M, down 4.7% from $208M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management deployed $7.91M of net new capital in Q1 2021, opening 1 new position. Its largest new stake was Societal CDMO, Inc. Common Stock: 2,202,420 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Athyrium Capital Management's largest Q1 2021 buy was Societal CDMO, Inc. Common Stock: 2,202,420 shares worth $6.14M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $198M portfolio in Q1 2021.
  • Athyrium Capital Management opened 1 new position and closed 0 in Q1 2021.
  • Athyrium Capital Management's portfolio value fell 4.7% quarter-over-quarter to $198M.

Based on Athyrium Capital Management's 13F filing for Q1 2021, filed 17 May 2021.